共 19 条
Rapidly fatal SMARCA4-deficient undifferentiated sarcoma originating from hybrid hemosiderotic fibrolipomatous tumor/pleomorphic hyalinizing angiectatic tumor of the foot
被引:5
作者:
Agaimy, Abbas
[1
]
Meidenbauer, Norbert
[2
,3
]
Sukov, William R.
[4
]
Stoehr, Robert
[1
]
Vieth, Michael
[1
,5
]
Roemer, Frank
[6
]
Grutzmann, Robert
[7
]
Folpe, Andrew L.
[4
]
机构:
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med 5, Erlangen, Germany
[3] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Med Oncol & Hematol, Erlangen, Germany
[4] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[5] Klinikum Bayreuth Gmbh, Inst Pathol, Bayreuth, Germany
[6] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Radiol, Erlangen, Germany
[7] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Surg, Erlangen, Germany
关键词:
SWI;
SNF complex;
Pleomorphic hyalinizing angiectatic tumor;
PHAT;
Hemosiderotic fibrolipomatous tumor;
HFLT;
SMARCA4;
Undifferentiated sarcoma;
MGEA5;
REARRANGEMENTS;
COMPONENT;
TGFBR3;
D O I:
10.1007/s00428-021-03167-6
中图分类号:
R36 [病理学];
学科分类号:
100104 ;
摘要:
Pleomorphic hyalinizing angiectatic tumor (PHAT) of soft parts and hemosiderotic fibrolipomatous tumor (HFLT) are two rare low-grade locally recurring neoplasms with predilection for the foot/ankle. Recent studies support a close link between the two entities, and origin of PHAT from HFLT and occurrence of hybrid HFLT/PHAT have been documented. Both lesions often harbor TGFBR3 or MGEA5 rearrangements. Rare sarcomas originating from HFLT/PHAT have been reported, typically resembling myxofibrosarcoma or myxoinflammatory fibroblastic sarcoma. We describe a novel SMARCA4-deficient undifferentiated sarcoma with rhabdoid features originating from hybrid HFLT/PHAT in the foot of a 54-year-old male. The tumor pursued a highly aggressive course with rapid regrowth after resection and multiple metastases resulting in patient's death within 5 months, despite systemic chemotherapy. Immunohistochemistry revealed SMARCA4 loss in the undifferentiated sarcoma, but not in the HFLT/PHAT. Molecular testing confirmed TGFBR3/MGEA5 rearrangements. This report expands the phenotypes of sarcomas developing from pre-existing PHAT/HFLT.
引用
收藏
页码:1115 / 1120
页数:6
相关论文